Enhancement of chemosensitivity toward peplomycin by calpastatin-stabilized NF-κB p65 in esophageal carcinoma cells: Possible involvement of Fas/Fas-L synergism

Apoptosis

Volumn 11, Issue 6, 2006, Pages 1025-1037

  Liu, T L ^a   Shimada, H ^a   Ochiai, T ^a   Shiratori, T ^a   Lin, S E ^a   Kitagawa, M ^a   Harigaya, K ^a   Maki, M ^b   Oka, M ^c   Abe, T ^c   Takiguchi, M ^a   Hiwasa, T ^a  

^a CHIBA UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

^c YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Calpain; Esophageal carcinoma; Fas; NF B; Peplomycin

Indexed keywords

BIOLOGICAL MARKER; CALPAIN; CALPASTATIN; CAMPTOTHECIN; COMPLEMENTARY DNA; CYTARABINE; ETOPOSIDE; FAS LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOMYCIN C; PEPLEOMYCIN;

ARTICLE; CANCER CELL; CELL LINE; CHEMOSENSITIVITY; CONTROLLED STUDY; DEGRADATION; DRUG SENSITIVITY; ENZYME ACTIVITY; ESOPHAGUS CARCINOMA; EXPRESSION VECTOR; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PURIFICATION; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, CD95; CALCIUM-BINDING PROTEINS; CARCINOMA; CELL LINE, TUMOR; ESOPHAGEAL NEOPLASMS; FAS LIGAND PROTEIN; HUMANS; PEPLOMYCIN; TRANSCRIPTION FACTOR RELA;

EID: 33745034073     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-006-6353-y     Document Type: Article

References (60)

1. Isono K, Ochiai T. Recent advances of treatment of cancer of the esophagus (review). Ann Cancer Res Ther 1992; 1: 9-16.
2. Houghton JA, Weiss KD, Williams LG, Torrance PM, Houghton PJ. Relationship between 5-fluoro-2′-deoxyundylate, 2′-deoxyuridylate, and thymidylate synthase activity subsequent to 5-fluorouracil administration, in xenografts of human colon adenocarcinomas. Biochem Pharmacol 1986; 35: 1351-1358.
3. Aschele C, Sobrero A, Faderan MA, Bertino JR. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 1992; 52: 1855-1864.
4. Oka S. A review of clinical studies of bestatin. Recent Results Cancer Res 1980; 75: 126-132.
5. 2 arrest after DNA damage. Science 1998; 282: 1497-1501.
6. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.
7. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-299.
8. Oda K, Arakawa H, Tanaka T, et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 2000; 102: 849-862.
9. Oda E, Ohki R, Murasawa H, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000; 288: 1053-1058.
10. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature 1997; 389: 300-305.
11. Hellin AC, Calmant P, Gielen J, Bours V, Merville MP. Nuclear factor-κ B-dependent regulation of p53 gene expression induced by daunomycin genotoxic drug. Oncogene 1998; 16: 1187-1195.
12. Tergaonkar V, Pando M, Vafa O, Wahl G, Verma I. p53 stabilization is decreased upon NFκB activation: A role for NFκB in acquisition of resistance to chemotherapy. Cancer Cell 2002; 1: 493-503.
13. Gilmore TD. The Rel/NF-κB signal transduction pathway: Introduction. Oncogene 1999; 18: 6842-6844.
14. Canty TG Jr, Boyle EM Jr, Farr A, Morgan EN, Verrier ED, Pohlman TH. Oxidative stress induces NF-κB nuclear translocation without degradation of IκBα. Circulation 1999; 9: II 361-364.
15. Ravi R, Mookerjee B, van Hensbergen Y, et al. p53-mediated repression of nuclear factor-κB RelA via the transcriptional integrator p300. Cancer Res 1998; 58: 4531-4536.
16. Ikeda A, Sun X, Li Y, et al. p300/CBP-dependent and - independent transcriptional interference between NF-κB RelA and p53. Biochem Biophys Res Commun 2000; 272: 375-379.
17. Kuhnel F, Zender L, Paul Y, et al. NFκB mediates apoptosis through transcriptional activation of Fas (CD95) in adenoviral hepatitis. J Biol Chem 2000; 275: 6421-6427.
18. Cohen PL, Eisenberg RA. Lpr and gld: Single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 1991; 9: 243-269.
19. Kinoshita H, Yoshikawa H, Shiiki K, Hamada Y, Nakajima Y, Tasaka K. Cisplatin (CDDP) sensitizes human osteosarcoma cell to Fas/CD95-mediated apoptosis by down-regulating FLIP-L expression. Int J Cancer 2000; 88: 986-991.
20. Mizutani Y, Wu XX, Yoshida O, Shirasaka T, Bonavida,B. Chemoimmunosensitization of the T24 human bladder cancer line to Fas-mediated cytotoxicity and apoptosis by cisplatin and 5-fluorouracil. Oncol Rep 1999; 6: 979-982.
21. Han Y, Weinman S, Boldogh I, Walker RK, Brasier AR. Tumor necrosis factor-α-inducible IκBα proteolysis mediated by cytosolic m-calpam. A mechanism parallel to the ubiquitin-proteasome pathway for nuclear factor-κB activation. J Biol Chem 1999; 274: 787-794.
22. Hiwasa T. Substrates for calpain, proteasome and caspase. Recent Res Devel Biochem 2003; 4: 629-642.
23. Lee FY, Kim DW, Karmin JA, et al. μ-calpain regulates receptor activator of NF-κB Ligand (RANKL)-supported osteoclastogenesis via NF-κB activation in RAW 264.7 cells. J Biol Chem 2005; 280: 29929-29936.
24. Sorimachi H, Suzuki K. The structure of calpain. J Biochem 2001; 129: 653-664.
25. Dear TN, Boehm T. Identification and characterization of two novel calpain large subunit genes. Gene 2001; 274: 245-252.
26. Ohno S, Emori Y, Imajoh S, Kawasaki H, Kisaragi, M, Suzuki K. Evolutionary origin of a calcium-dependent protease by fusion of genes for a thiol protease and a calcium-binding protein? Nature 1984; 312: 566-570.
27. 2+-dependent protease (calpain) and its high-molecular-weight endogenous inhibitor (calpastatin). Adv Enzyme Regul 1980; 19: 407-424.
28. Shimada H, Shimizu T, Ochiai T, et al. Preclinical study of adenoviral p53 gene therapy for esophageal cancer. Surg Today 2001; 31: 597-604.
29. Oka M, Hirose K, Iizuka N, et al. Cytokine mRNA expression patterns in human esophageal cancer cell lines. J Interferon Cytokine Res 1995; 15: 1005-1009.
30. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. Immunol Methods 1983; 65: 55-63.
31. Hiwasa T, Shimada H, Sakaida T, et al. Drug-sensitivity pattern analysis of study of functional relationship between gene products. FEBS Lett 2003; 552: 177-183.
32. Hiwasa T, Sawada T, Sakiyama S. Cysteine proteinase inhibitors and ras gene products share the same biological activities including transforming activity toward NIH3T3 mouse fibroblasts and the differentiation-inducing activity toward PC12 rat pheochromocytoma cells. Carcinogenesis 1990; 11: 75-80.
33. Hiwasa T. Induction of apoptosis by a calpain stimulator, ONO-3403. Apoptosis 1996; 1: 75-80.
34. Hiwasa T, Sakiyama S. Nuclear localization of procathepsin L/MEP in ras-transformed mouse fibroblasts. Cancer Lett 1996; 99: 87-91.
35. Inomata M, Nakamura M, Imajoh-Ohmi S, Kawashima S. A variety of calpain/calpastatin systems in mammalian erythrocytes. Biochim Biophys Acta 1993; 1178: 207-214.
36. Saido TC, Nagao S, Shiramine M, et al. Autolytic transition of mu-calpain upon activation as resolved by antibodies distinguishing between the pre- and post-autolysis forms. J Biochem 1992; 111: 81-86.
37. Sakao E, Ishihara A, Horikawa K, et al. Two-peaked synchronization in day/night expression rhythms of the fibrinogen gene cluster in the mouse liver. Biol Chem 2003; 278: 30450-30457.
38. Hitomi K, Yokoyama A, Maki M. Expression of biologically active human calpastatin in baculovirus-infected insect cells and in Escherichia coli. Biosci Biotechnol Biochem 1998; 62: 136-141.
39. Hiwasa T, Ma J, Ike Y, Katunuma N, Sakiyama S. Increase of cyclin B by overexpression of cystatin α. Cell Biochem Funct 1995; 13: 293-296.
40. Hiwasa T, Nakata M, Nakata M, et al. Regulation of transformed state by calpastatin via PKCε in NIH3T3 mouse fibroblasts. Biochem Biophys Res Commun 2002; 290: 510-517.
41. Mauxion F, Sen R. Alteration of a single nucleotide allows efficient binding of H2TF1/KBF1 to the immunoglobulin κ enhancer B motif. Mol Cell Biol 1989; 9: 3548-3552.
42. Kitagawa M, Oyama T, Kawashima T, et al. A human protein with sequence similarity to Drosophila mastermind coordinates the nuclear form of notch and a CSL protein to build a transcriptional activator complex on target promoters. Mol Cell Biol 2001; 21: 4337-4346.
43. Fujita T, Nolan GP, Liou H-C, Scott ML, Baltimore D. The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-κB p50 homodimers. Genes Develop 1993; 7: 1354-1363.
44. r-1 cells. FEBS Lett 1999; 459: 391-394.
45. Suzuki K, Nakajima H, Kagami S, et al. Proteolytic processing of Stat6 signaling in mast cells as a negative regulatory mechanism. J Exp Med 2002; 196: 27-38.
46. Shen J, Channavajhala P, Seldin DC, Sonenshem GE. Phosphorylation by the protein kinase CK2 promotes calpain-mediated degradation of IκBα. J Immunol 2001; 167: 4919-4925.
47. Bos JL, ras oncogenes in human cancer: A review. Cancer Res 1989; 49: 4682-4689.
48. Tamura K, Araki Y, Tateyama H, Maeda M, Seita M. Phase II trial of cis-diamminedichloroplatinum (cis-platinum), vincristine, and peplomycin for advanced squamous cell carcinoma. J Surg Oncol 1987; 35: 241-244.
49. Ghosh S, Mendoza T, Ortiz LA, et al. Bleomycin sensitivity of mice expressing dominant-negative p53 in the lung epithelium. Am J Respir Crit Care Med 2002; 166: 890-897.
50. Ueta E, Yoneda K, Kimura T, et al. Mn-SOD antisense upregulates in vivo apoptosis of squamous cell carcinoma cells by anticancer drugs and γ-rays regulating expression of the BCL-2 family proteins, COX-2 and p21. Int J Cancer 2001; 94: 545-550.
51. Yang HL, Dong YB, Elliott MJ, Liu TJ, McMasters KM. Caspase activation and changes in Bcl-2 family member protein expression associated with E2F-1-mediated apoptosis in human esophageal cancer cells. Clin Cancer Res 2000; 6: 1579-1589.
52. Sakaida T, Iwadate Y, Yamaji S, et al. Acquisition of drug resistance by constitutive suppression of NF-κB in ras-transformed NIH3T3 mouse fibroblasts. Int J Oncol 2003; 23: 1071-1077.
53. Zheng Y, Ouaaz F, Bruzzo P, Singh V, Gerondakis S, Beg AA. NF-κB RelA (p65) is essential for TNF-α-induced fas expression but dispensable for both TCR-induced expression and activation-induced cell death. J Immunol 2001; 166: 4949-4957.
54. Muraki Y, Tateishi A, Seta C, et al. Fas antigen expression and outcome of oral squamous cell carcinoma. Int J Oral Maxillofac Surg 2000; 29: 360-365.
55. Okamura H, Morimoto H, Haneji T. Peplomycin-induced apoptosis in oral squamous carcinoma cells depends on bleomycin sensitivity. Oral Oncol 2001; 37: 379-385.
56. Furusaka T, Kida A, lizuka N, Kikuchi K, Tomita H. Combination chemotherapy with CDDP, 5-FU and PEP in head and neck malignant tumors. Auris Nasus Larynx 1986; 13: Suppl. 1, S127-133.
57. Sakamoto K, Komatsu K, Matsumoto Y. The in vitro and in vivo antitumor effects of pepleomycin alone or in combination with radiation. Radiat Res 1985; 102: 224-231.
58. Eichhorst ST, Muerkoster S, Weigand MA, Krammer PH. The chemotherapeutic drug 5-fluorouracil induces apoptosis in mouse thymocytes in vivo via activation of the CD95 (APO-1/Fas) system. Cancer Res 2001; 61: 243-248.
59. Reap EA, Roof K, Maynor K, Borrero M, Booker J, Cohen PL. Radiation and stress-induced apoptosis: A role for Fas/Fas ligand interactions. Proc Natl Acad Sci USA 1997; 94: 5750-5755.
60. Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994; 73: 2013-2026.